August 17, 2016 04:28 PM EDT
R&D

Cerulean crash­es af­ter lead nano drug flubs its sec­ond PhII can­cer study

John Carroll

Editor & Founder

Cerulean Phar­ma’s lead nan­otech can­cer drug has run in­to an­oth­er stone wall in the clin­ic. The Waltham, MA-based biotech $CERU says that CR­LX101 com­bined …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: Two Vi­da Ven­tures co-founders ex­it the VC firm

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Wal­greens in talks to sell to pri­vate eq­ui­ty — re­port

Roche ini­tial­ly did­n't want to buy Po­sei­da — and part­ner Astel­las did­n't sub­mit an of­fer, new fil­ings show

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times